A Phase 2 Randomized Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections
Latest Information Update: 14 May 2025
At a glance
- Drugs Gelsolin (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors BioAegis Therapeutics
Most Recent Events
- 06 May 2025 According to a BioAegis Therapeutics media release, the company announced the site activation and patient recruitment underway in 13 countries in this trial.
- 18 Mar 2025 According to a BioAegis Therapeutics media release, comapny will present data from this study at MedInvest Biotech & Pharma Investor Conference in New York City on March 27, 2025 and the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium from March 18-21, 2025.
- 17 Oct 2024 According to a BioAegis Therapeutics media release, company announced that the the first patient has been enrolled in the company Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress Syndrome (ARDS).